Studies / Phase III
APROMISS: catequentinib (AL3818) in ASPS, leiomyosarcoma and synovial sarcoma
recruiting
Design
- APROMISS: catequentinib (AL3818) in ASPS, leiomyosarcoma and synovial sarcoma
- Randomised by cohort: LMS vs placebo; SS 2:1 vs dacarbazine; ASPS single-arm
- Catequentinib (AL3818), oral multi-kinase TKI (VEGFR1-3, FGFR1-4, PDGFR, c-Kit, RET)
- ORR (ASPS); PFS (LMS, SS)
Lifecycle
0 of 13 doneFeasibility assessed
not started
Protocol drafted & medically reviewed
not started
Sites activation-ready
not started
Recruitment funnel and screening plan
not started
Sites risk-scored
not started
Data cleaned
not started
Safety reports triaged
not started
Dropout risk scored
not started
Termination risk watched
not started
Drug supply forecast
not started
TLFs generated & validated
not started
CSR drafted & signed off
not started
TMF inspection-ready
not started
Sites
0No sites contracted for this study yet.